Evidence map›Paper›PMID 36037221›Full record

ArticlePLoS genetics2022

Mechanistic insights into global suppressors of protein folding defects.

Gopinath Chattopadhyay, Jayantika Bhowmick, Kavyashree Manjunath, Shahbaz Ahmed, Parveen Goyal, Raghavan Varadarajan

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Targeting p53 pathways: mechanisms, structures, and advances in therapy.Signal transduction and targeted therapy · 2023
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Opinion: Protein folds vs. protein folding: Differing questions, different challenges.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  9. Article
  10. Structural and functional determinants inferred from deep mutational scans.Protein science : a publication of the Protein Society · 2022
    Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gopinath ChattopadhyayMolecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
Jayantika BhowmickMolecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
Kavyashree ManjunathCentre for Chemical Biology and Therapeutics, Institute For Stem Cell Science and Regenerative Medicine, Bangalore, India.ORCID 0000-0002-1838-5362
Shahbaz AhmedMolecular Biophysics Unit, Indian Institute of Science, Bangalore, India.
Parveen GoyalInstitute for Stem Cell Science and Regenerative Medicine, Bangalore, India.ORCID 0000-0002-7808-8298
Raghavan VaradarajanMolecular Biophysics Unit, Indian Institute of Science, Bangalore, India.ORCID 0000-0002-0823-7577
Indian Institute of Science Bangalore · INInstitute for Stem Cell Biology and Regenerative Medicine · IN

Funding

Wellcome Trust
6 · The paper itself

Abstract

Most amino acid substitutions in a protein either lead to partial loss-of-function or are near neutral. Several studies have shown the existence of second-site mutations that can rescue defects caused by diverse loss-of-function mutations. Such global suppressor mutations are key drivers of protein evolution. However, the mechanisms responsible for such suppression remain poorly understood. To address this, we characterized multiple suppressor mutations both in isolation and in combination with inactive mutants. We examined six global suppressors of the bacterial toxin CcdB, the known M182T global suppressor of TEM-1 β-lactamase, the N239Y global suppressor of p53-DBD and three suppressors of the SARS-CoV-2 spike Receptor Binding Domain. When coupled to inactive mutants, they promote increased in-vivo solubilities as well as regain-of-function phenotypes. In the case of CcdB, where novel suppressors were isolated, we determined the crystal structures of three such suppressors to obtain insight into the specific molecular interactions responsible for the observed effects. While most individual suppressors result in small stability enhancements relative to wildtype, which can be combined to yield significant stability increments, thermodynamic stabilisation is neither necessary nor sufficient for suppressor action. Instead, in diverse systems, we observe that individual global suppressors greatly enhance the foldability of buried site mutants, primarily through increase in refolding rate parameters measured in vitro. In the crowded intracellular environment, mutations that slow down folding likely facilitate off-pathway aggregation. We suggest that suppressor mutations that accelerate refolding can counteract this, enhancing the yield of properly folded, functional protein in vivo.

Indexed as

COVID-19SARS-CoV-2HumansMutationProtein FoldingProteinsSuppression, GeneticProteins

Identifiers

PMID36037221
PMCPMC9491731
OpenAlexW4293469948

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.